| Autor: |
Avent ND; Centre for Research in Biomedicine and Bristol Genomics Research Institute, Faculty of Applied Sciences, University of the West of England, Bristol, UK., Martinez A, Flegel WA, Olsson ML, Scott ML, Nogués N, Písăcka M, Daniels GL, Muñiz-Diaz E, Madgett TE, Storry JR, Beiboer S, Maaskant-van Wijk PM, von Zabern I, Jiménez E, Tejedor D, López M, Camacho E, Cheroutre G, Hacker A, Jinoch P, Svobodova I, van der Schoot E, de Haas M |
| Jazyk: |
angličtina |
| Zdroj: |
Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie [Transfus Med Hemother] 2009; Vol. 36 (3), pp. 162-167. Date of Electronic Publication: 2009 May 28. |
| DOI: |
10.1159/000218192 |
| Abstrakt: |
The Bloodgen project was funded by the European Commission between 2003 and 2006, and involved academic blood centres, universities, and Progenika Biopharma S.A., a commercial supplier of genotyping platforms that incorporate glass arrays. The project has led to the development of a commercially available product, BLOODchip, that can be used to comprehensively genotype an individual for all clinically significant blood groups. The intention of making this system available is that blood services and perhaps even hospital blood banks would be able to obtain extended information concerning the blood group of routine blood donors and vulnerable patient groups. This may be of significant use in the current management of multi-transfused patients who become alloimmunised due to incomplete matching of blood groups. In the future it can be envisaged that better matching of donor-patient blood could be achieved by comprehensive genotyping of every blood donor, especially regular ones. This situation could even be extended to genotyping every individual at birth, which may prove to have significant long-term health economic benefits as it may be coupled with detection of inborn errors of metabolism. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
